Provided by Tiger Trade Technology Pte. Ltd.

Alexander's

246.11
-3.6600-1.47%
Post-market: 246.110.00000.00%19:26 EDT
Volume:30.48K
Turnover:7.53M
Market Cap:1.26B
PE:61.37
High:249.78
Open:249.59
Low:245.00
Close:249.77
52wk High:260.84
52wk Low:201.28
Shares:5.11M
Float Shares:2.13M
Volume Ratio:1.09
T/O Rate:1.43%
Dividend:18.01
Dividend Rate:7.32%
EPS(TTM):4.01
EPS(LYR):5.50
ROE:16.21%
ROA:3.09%
PB:13.85
PE(LYR):44.78

Loading ...

Stock Track | Alexander's Plummets 5.44% Intraday After Q4 Earnings and Revenue Miss Estimates

Stock Track
·
Feb 09

Alexander's net income, revenue fall in Q4

Reuters
·
Feb 09

Earnings Flash (ALX) Alexander's Posts Q4 Non-GAAP FFO $2.43 a Share, vs. FactSet Est of $2.74

MT Newswires Live
·
Feb 09

BRIEF-Alexander's Q4 Adjusted FFO Per Share USD 2.43

Reuters
·
Feb 09

Alexander’s Announces Fourth Quarter Financial Results

THOMSON REUTERS
·
Feb 09

Alexander's Q4 Net Income USD 3.824 Million

THOMSON REUTERS
·
Feb 09

Alexander's Q4 Adjusted Ffo per Share USD 2.43

THOMSON REUTERS
·
Feb 09

Alexander's Q4 Revenue USD 53.255 Million

THOMSON REUTERS
·
Feb 09

Alexander's Q4 FFO $2.43 Misses $3.02 Estimate, Sales $53.255M Miss $53.400M Estimate

Benzinga
·
Feb 09

Alexander's Inc. meldet für das Gesamtjahr 2025 einen Rückgang der Mieterlöse um 5,8 Prozent auf 213,18 Mio. USD

Reuters
·
Feb 09

ALX Oncology Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 05

Alexander's Keeps Quarterly Dividend at $4.50 a Share, Payable Feb. 27 to Shareholders of Record on Feb. 17

MT Newswires Live
·
Feb 05

Alexander's Inc. zahlt Quartalsdividende von 4,50 US-Dollar je Aktie

Reuters
·
Feb 05

Alexander's Inc. Declares $4.50 Quarterly Dividend

Reuters
·
Feb 05

Earning Preview: Alexander's Q4 revenue is expected to decrease by 3.26%, and institutional views are limited and cautious

Earnings Agent
·
Feb 02

What Atlas Arteria (ASX:ALX)'s Q4 Toll Revenue Growth Means For Shareholders

Simply Wall St.
·
Feb 02

ALX Oncology announces major underwritten public equity offering

TIPRANKS
·
Jan 30

ALX Oncology Announces Pricing of Underwritten Offering

GlobeNewswire
·
Jan 30

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

GlobeNewswire
·
Jan 30

ALX Oncology Expands Inducement Equity Plan for Hiring

TIPRANKS
·
Jan 22